title: The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
abstract: OBJECTIVE
  Histone deacetylase inhibitors (HDACis) are a promising class of anticancer agents for the treatment of brain tumors. HDACis can increase the expression of brain-derived neurotrophic factor (BDNF) in brain cells. We have previously shown that BDNF reduces the viability of medulloblastoma cells. The aim of the present study was to examine the effect of the HDACi sodium butyrate (NaB) combined with human recombinant BDNF (hrBDNF), on the viability of human medulloblastoma cell lines.
  
  
  METHODS
  DAOY and ONS76 medulloblastoma cells were treated with NaB, hrBDNF, or NaB combined with hrBDNF. Cell viability was measured with the MTT assay.
  
  
  RESULTS
  NaB combined with hrBDNF significantly reduced the viability of DAOY medulloblastoma cells. In ONS76 cells, NaB alone reduced viability, but the effect was not potentiated by hrBDNF.
  
  
  CONCLUSIONS
  These findings provide early evidence for a rationale supporting further evaluation of HDACis and BDNF as a new combinatorial approach to inhibit the growth of medulloblastoma.
authors.affiliation: Cancer Research Laboratory, University Hospital Research Center (CPE-HCPA), Porto Alegre, RS, Brazil.
authors.forename: Carolina
authors.initials: C
authors.lastname: Nör
authors.forename: Caroline Brunetto
authors.initials: CB
authors.lastname: de Farias
authors.forename: Ana Lucia
authors.initials: AL
authors.lastname: Abujamra
authors.forename: Gilberto
authors.initials: G
authors.lastname: Schwartsmann
authors.forename: Algemir Lunardi
authors.initials: AL
authors.lastname: Brunetto
authors.forename: Rafael
authors.initials: R
authors.lastname: Roesler
mesh_terms: D019208:Brain-Derived Neurotrophic Factor / Q000008:administration & dosage*; D002087:Butyrates / Q000008:administration & dosage* / Q000737:chemistry; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002528:Cerebellar Neoplasms / Q000188:drug therapy / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D008527:Medulloblastoma / Q000188:drug therapy / Q000473:pathology*
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D002087:Butyrates; D056572:Histone Deacetylase Inhibitors